These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9021380)

  • 1. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study.
    Crosignani PG; De Cecco L; Gastaldi A; Venturini PL; Oldani S; Vegetti W; Sémino A; La Commare P; Vercellini P
    Hum Reprod; 1996 Dec; 11(12):2732-5. PubMed ID: 9021380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD; Surrey ES; Weisberg GW; Casino LA
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
    Bhatia S; Neely EK; Wilson DM
    Pediatrics; 2002 Feb; 109(2):E30. PubMed ID: 11826240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.
    Gerhard I; Schindler AE; Bühler K; Winkler U; Meinen K; Mancarella D; Hoffmann G; Schüssler B; Kimmig R; Kranzfelder D
    Clin Ther; 1992; 14 Suppl A():3-16. PubMed ID: 1535021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.
    Agarwal SK; Hamrang C; Henzl MR; Judd HL
    J Reprod Med; 1997 Jul; 42(7):413-23. PubMed ID: 9252932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results.
    Wheeler JM; Knittle JD; Miller JD
    Am J Obstet Gynecol; 1992 Nov; 167(5):1367-71. PubMed ID: 1442992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.
    Ling FW
    Obstet Gynecol; 1999 Jan; 93(1):51-8. PubMed ID: 9916956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin.
    Dawood MY; Ramos J; Khan-Dawood FS
    Fertil Steril; 1995 Jun; 63(6):1177-83. PubMed ID: 7750585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.
    Crosignani PG; Luciano A; Ray A; Bergqvist A
    Hum Reprod; 2006 Jan; 21(1):248-56. PubMed ID: 16176939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study].
    Schindler AE; Bühler K; Gerhard I; Wiedemann R; Kimmig R; Schüssler B; Kranzfelder D; Mall-Häfeli M; Meinen K; Mancarella D
    Zentralbl Gynakol; 1994; 116(12):679-86. PubMed ID: 7846980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
    Schlaff WD; Carson SA; Luciano A; Ross D; Bergqvist A
    Fertil Steril; 2006 Feb; 85(2):314-25. PubMed ID: 16595206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group.
    Fertil Steril; 1996 Dec; 66(6):911-9. PubMed ID: 8941054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group.
    Wheeler JM; Knittle JD; Miller JD
    Am J Obstet Gynecol; 1993 Jul; 169(1):26-33. PubMed ID: 8333471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
    Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.